TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05573685

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo App
Description: Placebo App to be used in patients with 1 of the 4 indications of rheumatoid arthritis, fibromyalgia Irritable Bowel Syndrome, Diabetic Neuropathy
Study: NCT05422144

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Antimicrobial Skin & Wound Cleanser (AWC)
Description: BIAKŌS™ Antimicrobial Skin \& Wound Cleanser helps in the mechanical removal of debris and foreign material from the skin, wound, or application site. BIAKŌS™ Antimicrobial Skin and Wound Cleanser is a pure, colorless, isotonic cleanser that is safe. The preservative, polyhexamethylene biguanide (PHMB), at a concentration of 0.1% w/w is added to the product to inhibit the growth of microorganisms such as Staphylococcus aureus, Staphylococcus epidermidis, Pseudomonas aeruginosa, Escherichia coli, antibiotic resistant Methicillin Resistant Staphylococcus aureus (MRSA). and fungus Candida albicans within the product.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Antimicrobial Wound Gel (AWG)
Description: BIAKŌS Antimicrobial Wound Gel provides a moist environment to wound surfaces. BIAKŌS Antimicrobial Wound Gel is a safe and gentle colorless gel. The gel provides preservative properties through the antimicrobial polyhexamethylene biguanide (PHMB).~BIAKŌS Antimicrobial Wound Gel:~* Resists microbial colonization within the gel during shelf storage.~* Provides an amorphous gel covering.~* Facilitates autolytic debridement through a moist wound environment. Wounds experience some level of autolytic debridement in which the body's own enzymes breakdown necrotic tissue.
Study: NCT05893082

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: F2 Filter and Delivery System
Description: Placement of F2 device in aorta to cover the great cerebral vessels.
Study: NCT06338449

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic training (AT)
Description: An exercise program was developed by a full-time physical education teacher, with all group exercises conducted at the outdoor track and field facility of Xuzhou Medical University. Participants in the aerobic training group, after completing a warm-up, were required to perform moderate-intensity aerobic running for 60 minutes per session, 4-5 times a week. The exercise intensity was set to reach 50%-70% of the maximum heart rate (Maximum heart rate = 220 - age). The exercise sessions were scheduled in the evening after dinner, from 17:30 to 19:00.All participants were continuously intervened for 8 weeks.
Study: NCT05492032

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active-tDCS
Description: For active-tDCS condition, participants will receive stimulation on the dorsolateral prefrontal cortex with ramp up and ramp down mode for 10 seconds, eliciting a tingling sensation on the scalp that fades over seconds. Following that, a twenty-minute executive functional training task will be initiated five minutes subsequent to the stimulation mode, and the stimulation will be terminated when the training task ends.
Study: NCT06338449

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance training (RT)
Description: Participants in the resistance training group were required to complete moderate-intensity resistance exercises 4-5 times per week. Each session included a warm-up, followed by exercises such as knee lifts with torso twists, knee-to-hand taps under the hips, jumping jacks, burpees, sit-ups, planks, and squats. The routine was structured to perform 5-6 exercises per session, with 6-8 repetitions for each set. There was a 30-second rest interval between sets, and the total exercise time was 60 minutes. The timing for these exercise sessions was the same as for the AT group, conducted in the evening after dinner.All participants were continuously intervened for 8 weeks.
Study: NCT06517797

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: S1B-509
Description: S1B-509 has multiple neurotransmitter activities
Study: NCT06338449

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Combined aerobic and resistance training (AT + RT)
Description: Participants in the combined aerobic and resistance training (AT+RT) group started their sessions with a warm-up, followed by 30 minutes of aerobic running. After the aerobic training, they engaged in resistance training. The resistance training regimen was the same as that for the RT group, except that the duration of the resistance training was shorter. The total duration of the exercise session was 60 minutes.All participants were continuously intervened for 8 weeks.
Study: NCT05399693

Intervention type: PROCEDURE
Intervention: platelet transfusion
Description: platelet transfusion realised for Hematopoietic stem cells graft or for acute leukemia

Intervention type: PROCEDURE
Intervention: platelet transfusion
Description: platelet transfusion realised for Hematopoietic stem cells graft or for acute leukemia
Study: NCT06288386

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GrandioSO Heavy Flow
Description: Attachment will be performed with GrandioSO Heavy Flow.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Filtek Z350XT Flowable
Description: Attachment will be performed with Filtek Z350XT Flowable.
Study: NCT06388720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin-c 40mg/20ml and Gemcitabine 2000mg/50ml
Description: Intravesical sequential treatment of Mitomycin-c 40mg/20ml and Gemcitabine 2000mg/50ml.
Study: NCT05728801

Intervention type: DIAGNOSTIC_TEST
Intervention: Ageing
Description: Using comprehensive cognitive tests to quality the domain-specific cognitive changes during ageing.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ageing
Description: Using comprehensive cognitive tests to quality the domain-specific cognitive changes during ageing.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ageing
Description: Using comprehensive cognitive tests to quality the domain-specific cognitive changes during ageing.
Study: NCT06342167

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Interventions consist of 50-60 Gy in 25-30 fractions of radiotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Programmed Cell Death Protein 1 Inhibitor
Description: 200 mg of Sintilimab administered every three weeks concurrently with radiotherapy and after radiotherapy as consolidation therapy up to 1year.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Immunonutrition support
Description: 600-1600 ml of TPF-T per day according to the nutrition status evaluation
Study: NCT05153005

Intervention type: OTHER
Intervention: examination methods
Description: Some advanced methods: mannose protein (Mp1p), (1,3)- β- D-glucan (G antigen) and Cryptococcus capsular antigen (CrAg) serological detection, qPCR, dd- PCR and mass spectrometry identification, QFC.

Intervention type: OTHER
Intervention: examination methods
Description: Some advanced methods: mannose protein (Mp1p), (1,3)- β- D-glucan (G antigen) and Cryptococcus capsular antigen (CrAg) serological detection, qPCR, dd- PCR and mass spectrometry identification, QFC.

Intervention type: OTHER
Intervention: examination methods
Description: Some advanced methods: mannose protein (Mp1p), (1,3)- β- D-glucan (G antigen) and Cryptococcus capsular antigen (CrAg) serological detection, qPCR, dd- PCR and mass spectrometry identification, QFC.
Study: NCT05185232

Intervention type: OTHER
Intervention: Impact of gaps in care/loss to healthcare follow-up
Description: There will not be a discrete intervention as part of this study but study investigators will be examining a set of primary and secondary outcomes in patients who have followed recommended cardiac care vs. those who have not.

Intervention type: OTHER
Intervention: Impact of gaps in care/loss to healthcare follow-up
Description: There will not be a discrete intervention as part of this study but study investigators will be examining a set of primary and secondary outcomes in patients who have followed recommended cardiac care vs. those who have not.
Study: NCT05994651

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tidal Model improvement model
Description: 1. st interview Pre-assessment Application of measurement tools~2. nd meeting Orientation Concept of recovery, change phase of the individual, Holistic Evaluation, Creation of Personal Safety Plan 3. Interview Process planning Setting goals, Starting One-on-One Sessions~4th meeting Healing is possible, accepting his illness, overcoming change, emphasizing his strengths, instilling hope 5.-6. interview Empowerment Coping with crisis, reducing anxiety, relaxation exercises, individual roles, assertiveness, strengthening self-esteem 7.-8. Interview Maintaining control of life, taking responsibility for behavior, appropriate expression of anger, feeling, thinking and Taking responsibility for recovery, discovering behaviors 9th interview Creating a supportive environment Increasing new interactions, relationships, social skills 10th meeting Evaluation Finalizing the personal security plan, using new knowledge and behaviors in the healing journey, evaluation of the process
Study: NCT05886192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: norepinephrine+vasopressin
Description: Norepinephrine combined with vasopressin to maintain blood pressure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Norepinephrine
Description: norepinephrine
Study: NCT05457452

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Knee Brace
Description: Installation of an angle-adjustable knee brace, used after ACL reconstruction performed by an orthopedic specialist or orthopedic PPDS with the first week the angle locked at 00, in the second week the angle 0-900, in the third week the angle 0-1200, and the fourth week the angle of flexion full. Braces are used except for physical therapy according to the rehabilitation protocol in the first week.
Study: NCT06517797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1B-509
Description: S1B-509 has multiple neurotransmitter activities
Study: NCT05999539

Intervention type: DEVICE
Intervention: Transtibial prosthesis
Description: A transtibial prosthesis to be used for at least one year.

Intervention type: DEVICE
Intervention: Transtibial prosthesis
Description: A transtibial prosthesis to be used for at least one year.
Study: NCT05204875

Intervention type: RADIATION
Intervention: X-ray Velocimetry
Description: X-ray Velocimetry (XV) technology images the motion of the lungs, determines airway volumes and measures regional lung ventilation during spontaneous breathing.
Study: NCT06383845

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ESP Block
Description: ultrasound guided block with injection of Ropivacaine
Study: NCT06633913

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: spTMS-TBS-spTMS
Description: This study uses fMRI in combination with single-pulse TMS (spTMS) and theta-burst stimulation (TBS) to determine if the two effects coming from each are related to one another, and if there will be changes in brain activity when undergoing spTMS that are induced by TBS. Additionally, by stimulating the dlPFC in both patients and healthy controls with this paradigm, researchers are able to specifically compare the after-TBS single-pulse TMS-evoked brain responses with before-TBS responses to observe if TBS will change neural pathways disrupted in those who display high negative affect (e.g. depression, anxiety).
Study: NCT06011876

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Intermittent Hypoxia (AIH)
Description: AIH (acute intermittent hypoxia) consists of short episodes of low oxygen (9% O2).
Study: NCT04757844

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional Near-Infrared Spectroscopy (fNIRS)
Description: The hemodynamic response in prefrontal cortex will be measured using an Octamon+ system (Artinis). Eight emission and two detector probes will be arranged on the participant's forehead.
Study: NCT05239195

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Video Laryngoscope
Description: Laryngoscope with a camera and a video screen

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Direct Laryngoscope
Description: Laryngoscope without a camera or a video screen
Study: NCT06042166

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connecting and Reflecting Experience (CARE) Program
Description: The intervention consists of a 12-session mentalizing-focused parenting group, which will involve weekly one-hour telehealth therapy sessions with up to 7 postpartum parents per group and 1 to 2 facilitators. CARE is a therapy focused on parents' reflective capacity, or the ability to consider how our own and our children's thoughts, feelings, intentions, and other mental states shape behavior and parent-child relationships.
Study: NCT06464549

Intervention type: DIAGNOSTIC_TEST
Intervention: EEG-EOG recording at rest and during an auditory oddball paradigm
Description: Participants will attend an electroencephalogram-electrooculogram (EEG-EOG) recording session. Eye blinking will be examined during a rest condition (duration: 8 min) and during an active auditory oddball task (duration: 8 min), consisting of randomly intermixed tones (non-target: 500 Hz, overall probability: 80%, n=312; target: 1000 Hz, overall probability: 20%, n=78) presented with a 1-s inter-stimulus interval through headphones.

Intervention type: DIAGNOSTIC_TEST
Intervention: EEG-EOG recording at rest and during an auditory oddball paradigm
Description: Participants will attend an electroencephalogram-electrooculogram (EEG-EOG) recording session. Eye blinking will be examined during a rest condition (duration: 8 min) and during an active auditory oddball task (duration: 8 min), consisting of randomly intermixed tones (non-target: 500 Hz, overall probability: 80%, n=312; target: 1000 Hz, overall probability: 20%, n=78) presented with a 1-s inter-stimulus interval through headphones.
Study: NCT06370104

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Cognitive Behavioral Therapy for Suicide Prevention
Description: see arm description

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Living under control
Description: see arm description
Study: NCT06103812

Intervention type: DEVICE
Intervention: Hyalo4 Skin Gel
Description: The evaluation of performance and safety of Hyalo4 Skin Gel in the amelioration of bed wound appearance after 14 days of treatment.
Study: NCT06339762

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Compassion Training
Description: Self-Compassion Training
Study: NCT06011876

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Intermittent Hypoxia (AIH)
Description: AIH (acute intermittent hypoxia) consists of short episodes of low oxygen (9% O2).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Intermittent Hypercapnic-Hypoxia (AIHH)
Description: AIHH consists of short episodes of low oxygen (9% O2) and elevated carbon dioxide (4% CO2).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Intermittent Hypercapnic-Hypoxia (AIHH)
Description: AIHH consists of short episodes of low oxygen (9% O2) and elevated carbon dioxide (4% CO2).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham AIH
Description: A single session of sham AIH with episodes of normal room air (21% O2).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham AIH
Description: A single session of sham AIH with episodes of normal room air (21% O2).
Study: NCT06293482

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlear™ Nucleus® System
Description: The Cochlear™ Nucleus ® System is a commercially available system intended for restoration of hearing sensation through electrical stimulation of the auditory nerve in adult patients with bilateral symmetrical sensorineural hearing loss.
Study: NCT06720389

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: peri implant bone loss was assessed by CBCT
Description: using CBCT, vertical bone loss (VBL) was measured at baseline (T0), at1 year(T1), at 3 years(T3)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: peri implant bone loss was assessed by CBCT
Description: using CBCT, vertical bone loss (VBL) was measured at baseline (T0), at1 year(T1), at 3 years(T3)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: posterior ridge resorption was assessed by CBCT
Description: posterior ridge resorption was assessed by CBCT at baseline (T0), at 1 year( T1), at 3 years (T3). By superimposition of pre and post CBCT.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: posterior ridge resorption was assessed by CBCT
Description: posterior ridge resorption was assessed by CBCT at baseline (T0), at 1 year( T1), at 3 years (T3). By superimposition of pre and post CBCT.
Study: NCT05326880

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ceramic Dental Implant
Description: The ceramic implant will be placed in healed extraction sockets in the premolar-to-premolar area in the mandible and maxilla for single tooth replacement followed by prosthetic loading with definitive prosthesis after 6 months healing time. Type 4 surgery will be performed as defined by the ITI Consensus Statements for Implant Placement in Extraction Sockets: healed sites, typically around 16 weeks after tooth was extracted or after tooth was lost to allow complete healing of the ridge as well as soft- and hard tissue maturation. Both SG and CG receive routine treatment, only the choice of the implant material is defined by the study protocol.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Titanium Dental Implant
Description: The titanium implant will be placed in healed extraction sockets in the premolar-to-premolar area in the mandible and maxilla for single tooth replacement followed by prosthetic loading with definitive prosthesis after 6 months healing time. Type 4 surgery will be performed as defined by the ITI Consensus Statements for Implant Placement in Extraction Sockets: healed sites, typically around 16 weeks after tooth was extracted or after tooth was lost to allow complete healing of the ridge as well as soft- and hard tissue maturation. Both SG and CG receive routine treatment, only the choice of the implant material is defined by the study protocol.
Study: NCT06728761

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Breathalyser for measurement of the level of exhaled ethanol
Description: Breathalyser performed during the intake visit, and 15, 90, 180 and 300 min (if the exhaled alcohol level measured at 180 minutes was greater than 0.25 mg/l of breath) after the end of the meal.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Discomfort
Description: discomfort will be assessed using seven-choice Likert scales immediately before the test drink ingestion and 90 min and 180 min after the end of the standardized meal.
Study: NCT05882630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib,Serplulimab,Etoposide,Carboplatin
Description: In dose escalation, Surufatinib will be administered orally (PO) once daily (QD) ,d1-21,q3w + Serplulimab 4.5 mg/kg ivgtt,d1,q3w+Etoposide 100mg/m2,d1-3,q3w + Carboplatin AUC=5,d1,q3w; 4-6 cycles in total.~At the indication-specific expansion portion of the study, patients will receive surufatinib RP2D,d1-21,q3w+Serplulimab 4.5 mg/kg ivgtt,d1,q3w+Etoposide 100mg/m2,d1-3,q3w + Carboplatin AUC=5,d1,q3w, 4-6 cycles in total. After the end of the first-line treatment, patients with CR, PR, and SD can continue to maintenance treatment with Surufatinib RP2D,d1-21,q3w＋Serplulimab 4.5 mg/kg ivgtt,d1,q3w until the disease progressed.
Study: NCT06142227

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reading a Pictorial Storybook
Description: The pictorial storybook by children will be chosen by child psychologists. The book will be read to children by researcher. The researcher has a fairy tale therapy certificate. The pictorial storybook reading will start 15 minutes before the dental treatment process and will be completed before the treatment process begins.. The pictorial storybook will be read to children only one time.
Study: NCT06136988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel for Injection (Albumin-bound)
Description: Docetaxel for Injection (Albumin-bound) 60 or 75 mg/m\^2, Intravenous infusion, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SG001
Description: Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection, 360 mg, Intravenous infusion, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin for injection
Description: Cisplatin for injection, 25 mg/m\^2, Intravenous infusion, D1-D3, Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin for injection
Description: Cisplatin for injection, 25 mg/m\^2, Intravenous infusion, D1-D3, Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 135 mg/m\^2, Intravenous infusion, Q3W

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Simultaneous Radiotherapy
Description: Radiotherapy (28×1.8Gy)
Study: NCT06728761

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Discomfort
Description: discomfort will be assessed using seven-choice Likert scales immediately before the test drink ingestion and 90 min and 180 min after the end of the standardized meal.
Study: NCT06136988

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Simultaneous Radiotherapy
Description: Radiotherapy (28×1.8Gy)
Study: NCT03673735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab (one dose) before CRT and for 6 months Q4W after CRT

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: radiotherapy
Description: radiotherapy is administered in 33 fractions over 6.5 weeks fro a total of 66 Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: radiotherapy is administered in 33 fractions over 6.5 weeks fro a total of 66 Gy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo (one dose) before CRT and for 6 months Q4W after CRT

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin (100mg/m2) is administered at day 1, 22, 43 of radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin (100mg/m2) is administered at day 1, 22, 43 of radiotherapy
Study: NCT05292144

Intervention type: DEVICE
Intervention: Xperience Pro
Description: Patients in whom treatment with (Xperience Pro) has been attempted
Study: NCT06728761

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Appetite
Description: Appetite will be assessed using seven-choice Likert scales immediately before the test drink ingestion and 90 min and 180 min after the end of the standardized meal.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Appetite
Description: Appetite will be assessed using seven-choice Likert scales immediately before the test drink ingestion and 90 min and 180 min after the end of the standardized meal.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pregnancy urine test carried out during the intake visit on the day of the protocol
Description: Pregnancy urine test carried out during the intake visit on the day of the protocol for exclusion of pregnant woman.